Gross GN, et al. - In this double-blind study, researchers tested GSP301 nasal spray [a fixed-dose combination of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid)] for its efficacy and safety in patients with seasonal allergic rhinitis (SAR). Overall 1176 eligible patients (≥12 years of age) with SAR received either twice-daily GSP301 (665 μg of olopatadine and 25 μg of mometasone), olopatadine (665 μg), mometasone (25 μg), or placebo for 14 days, using randomization 1:1:1:1. Findings revealed the good tolerability as well as efficacy of GSP301 for treating SAR-associated nasal and ocular symptoms, in comparison to placebo. In adult and adolescent patients 12 years and older, GSP301 had a rapid onset of action of 15 minutes.